TERUMO HEART AND TERUMO CARDIOVASCULAR SYSTEMS SPONSOR 2010 MICHBIO EXPO AND CONFERENCE
ANN ARBOR, Michigan — October 26, 2010 — Terumo Heart, Inc. and Terumo Cardiovascular Systems (Terumo CVS), wholly owned subsidiaries of Terumo Corporation based in Ann Arbor, Michigan, today announced their joint corporate sponsorship of the 2010 MichBio Expo and Conference held October 26 and 27, at the Marriott at Eagle Crest in Ypsilanti, Michigan.
The Expo and Conference is the largest single gathering of biosciences professionals in the state, in 2009 attracting more than 500 participants and 60 exhibitors. Seventy percent of attendees are executives in biosciences companies, research institutions and universities and 25 percent represent service providers and other related industries.
"We are pleased that two of the premier medical device companies in southeast Michigan could support this important event,” said Stephen Rapundalo, Ph.D., President and CEO, MichBio. "Terumo has long been an anchor for economic growth in this community and our attendees will be interested in learning more about each organization's global leadership in the healthcare sector.”
Terumo Heart and Terumo CVS representatives will staff an onsite exhibit that will provide information about the companies to potential vendors, partners, and Associates. Additionally, both companies will host tours of their Ann Arbor facilities to provide attendees with an understanding of the companies' extensive product portfolios and manufacturing capabilities.
"Terumo is the 21st largest employer in Washtenaw County, Michigan, the second largest medical device manufacturer in Michigan, and an important part of Michigan's growing life sciences sector,” says Mark Sutter, President and CEO, Terumo Cardiovascular Systems. "As an important regional employer, we appreciate MichBio's effort to move the bioscience community toward becoming more integrated.”
"Both companies on the Terumo Ann Arbor campus continue to develop technology that is important to Michigan's emerging life sciences industry,” says William Pinon, President and CEO, Terumo Heart. "We are appreciative to be in a position to support the efforts of MichBio, while developing mutually beneficial relationships with the Expo's highly qualified attendees who may become future vendors, business partners or employees.”
For more information about Terumo Heart, Inc., visit www.terumoheart.com. For more information about Terumo Cardiovascular Systems, visit www.terumo-cvs.com. For more information about the 2010 MichBioExpo & Conference, visit www.michbio.org.
About Terumo Cardiovascular Systems Corporation
Terumo Cardiovascular Systems Corporation is a global manufacturer and marketer of medical devices for cardiac and vascular surgery. The company is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor; Elkton, Maryland; and Ashland, Massachusetts. For more information, visit www.terumo-cvs.com
About Terumo Heart, Inc.
Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. For more information visit www.terumoheart.com
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $3.0 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
Director, Corporate Communications
Terumo Cardiovascular Systems
(734) 657-6860 (cell)